EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares
What Happened
Luke Evnin, a director of Werewolf Therapeutics (HOWL), sold a total of 105,565 shares in three open‑market transactions executed under a Rule 10b5‑1 plan (dated March 26, 2026). The sales: 20,072 shares on 2026‑06‑04 (weighted avg ~$0.44, ~$8,832), 24,946 shares on 2026‑06‑05 (weighted avg ~$0.40, ~$9,978), and 60,547 shares on 2026‑06‑08 (weighted avg ~$0.40, ~$24,219). Total gross proceeds reported ≈ $43,029. These were sales (transaction code S), not purchases — routine monetization rather than a buy signal.
Key Details
- Transaction dates & reported weighted average prices:
- 2026-06-04: 20,072 sh @ $0.44 (proceeds $8,832); sold in multiple trades at $0.43–$0.4499.
- 2026-06-05: 24,946 sh @ $0.40 (proceeds $9,978); sold in multiple trades at $0.3918–$0.454.
- 2026-06-08: 60,547 sh @ $0.40 (proceeds $24,219); sold in multiple trades at $0.3706–$0.4126.
- Shares sold were allocated among related investment entities (per filing): AM LLC, MPM BioVentures 2014 (BV 2014), BV 2014(B), AM BV2014, and MPM Oncology Innovations Fund (MPM OIF). The filing breaks out how many shares each entity sold for each date.
- Reported holdings (by those entities) are shown in the filing lines associated with the sales (examples listed in the filing include holdings by entity such as AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF).
- Notable footnotes:
- Sales were effected pursuant to a 10b5‑1 trading plan (F1).
- Reported prices are weighted averages; the filing provides price ranges and offers to provide detailed per‑trade prices on request (F3, F7, F10).
- The filer disclaims beneficial ownership of the securities except to the extent of his pecuniary interest, as the shares are held through the listed investment vehicles (F4).
- Filing timeliness: the Form 4 was filed 2026‑06‑08 reporting trades from 2026‑06‑04 to 2026‑06‑08. The filing does not indicate a late‑filing flag.
Context
These are outright sales from investment vehicles associated with Luke Evnin, executed under a pre‑existing 10b5‑1 plan. Sales by directors are common for liquidity or portfolio reasons and do not by themselves indicate company performance or insider sentiment. Retail investors tracking insider activity may view purchases as stronger signals than routine sales; here the filing documents disposition and entity allocations rather than option exercises, gifts, or awards.
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-06-04$0.44/sh−20,072$8,832→ 462,704 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F6][F7][F4][F8]2026-06-05$0.40/sh−24,946$9,978→ 437,758 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F9][F10][F4][F11]2026-06-08$0.40/sh−60,547$24,219→ 377,211 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3706 to $0.4126 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 40,413 by AM LLC, 255,174 by BV 2014, 17,017 by BV 2014(B), 8,780 by AM BV2014 and 55,827 by MPM OIF.
- [F2]The shares were sold as follows: 2,150 by MPM Asset Management LLC ("AM LLC"), 13,578 by MPM BioVentures 2014, L.P. ("BV 2014"), 906 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 467 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,971 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.4499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 49,573 by AM LLC, 313,005 by BV 2014, 20,875 by BV 2014(B), 10,771 by AM BV2014 and 68,480 by MPM OIF.
- [F6]The shares were sold as follows: 2,673 by AM LLC, 16,874 by BV 2014, 1,126 by BV 2014(B), 581 by AM BV2014 and 3,692 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3918 to $0.454 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 46,900 by AM LLC, 296,131 by BV 2014, 19,749 by BV 2014(B), 10,190 by AM BV2014 and 64,788 by MPM OIF.
- [F9]The shares were sold as follows: 6,487 by AM LLC, 40,957 by BV 2014, 2,732 by BV 2014(B), 1,410 by AM BV2014 and 8,961 by MPM OIF.
Signature
/s/ Luke Evnin|2026-06-08